Biotech Co. To Pay $4M To End Presentation Hype Suit

A biopharmaceutical company acquired by Gilead Sciences will pay $4 million to resolve class claims in New Jersey federal court alleging it misled investors into expecting that new drug results would...

Already a subscriber? Click here to view full article